CORDIS - EU research results

A game change in continuous biosensing: Molecularly engineered affinity-based nanoswitches for personal monitoring

Project description

Continuous biosensing goes beyond glucose for better personal monitoring

The composition of blood is typically evaluated with blood tests, to reveal abnormalities associated with diseases or metabolism as well as changes related to ageing or menopause. For some time, diabetics have benefitted from continuous glucose monitoring (CGM) via a tiny sensor under the skin that reports glucose levels in real time. CGM has minimised the need for repetitive blood tests while enhancing the temporal resolution of changes, altering the course of the disease for many. The EU-funded CONSENSE project is now developing new sensor technologies suited for measuring a wealth of other biomolecules that are critical to health status, for truly personalised medicine and better outcomes.


Generic technology that allows continuous sensing of a wide range of biomolecular parameters could revolutionise patient monitoring and enable truly personalised therapy. Commercial sensors are available for continuous monitoring of glucose, but do not exist for other molecules that are important for monitoring disease status and treatment effect, including peptides, proteins, hormones, and drugs. The ambition of CONSENSE is to provide a game change in continuous biomolecular sensing by combining advanced molecular engineering with tailored optical detection technologies to yield generic, affinity-based biosensing technologies. CONSENSE will focus on the construction of biomolecular nanoswitches that translate molecular binding into robust and well-defined conformational changes at length scales that can be detected by selected optical detection methods, providing unique possibilities to distinguish between specific and nonspecific binding. While the applications for this new technology are wide and varied, within CONSENSE we will focus on immune monitoring in critical care settings, where patients have an urgent need for continuous monitoring related to inflammation and immunotherapy. CONSENSE brings together internationally leading pioneers in biomolecular switch engineering with research groups that have an excellent track record in biosensor development using advanced optical approaches, including two high-tech companies that have spun out from these groups. The consortium is completed by a strong network of partner industries and organisations, including four large medical technology companies, clinical experts, and seven SMEs providing specific technological expertise and training. The consortium will provide exceptional training to 15 ESRs, allowing them to develop professionally and perform world-class research that will fundamentally advance the field of continuous biomolecular monitoring for healthcare.


Net EU contribution
€ 1 062 479,52
5612 AE Eindhoven

See on map

Zuid-Nederland Noord-Brabant Zuidoost-Noord-Brabant
Activity type
Higher or Secondary Education Establishments
Total cost
€ 1 062 479,52

Participants (10)